KPX Lifescience.Co.Ltd (114450) - Cash Flow Conversion Efficiency
Based on the latest financial reports, KPX Lifescience.Co.Ltd (114450) has a cash flow conversion efficiency ratio of 0.095x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.33 Billion ≈ $2.26 Million USD) by net assets (₩35.13 Billion ≈ $23.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 114450 stock market capitalisation for the company's overall valuation and market capitalisation.
KPX Lifescience.Co.Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how KPX Lifescience.Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
KPX Lifescience.Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KPX Lifescience.Co.Ltd ranked by their cash flow conversion efficiency. Explore 114450 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Resverlogix Corp.
TO:RVX
|
0.010x |
|
Pantera Silver Corp
V:PNTR
|
-0.027x |
|
Alpcot Holding AB Series B
ST:ALPCOT-B
|
-0.159x |
|
Ulima Nitra PT
JK:UNIQ
|
0.040x |
|
Panca Global Securities Tbk
JK:PEGE
|
-0.129x |
|
Hamashbir 365 Holdings Ltd
TA:MSBI
|
0.659x |
|
Fuji Finance Indonesia Tbk PT
JK:FUJI
|
0.122x |
|
Bluglass Ltd
AU:BLG
|
0.000x |
Annual Cash Flow Conversion Efficiency for KPX Lifescience.Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of KPX Lifescience.Co.Ltd from 2014 to 2024. View KPX Lifescience.Co.Ltd (114450) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩35.75 Billion ≈ $24.23 Million |
₩525.49 Million ≈ $356.12K |
0.015x | +42.84% |
| 2023-12-31 | ₩35.95 Billion ≈ $24.37 Million |
₩370.02 Million ≈ $250.76K |
0.010x | +111.90% |
| 2022-12-31 | ₩52.64 Billion ≈ $35.67 Million |
₩-4.55 Billion ≈ $-3.08 Million |
-0.086x | -896.27% |
| 2021-12-31 | ₩56.30 Billion ≈ $38.15 Million |
₩611.38 Million ≈ $414.33K |
0.011x | -66.11% |
| 2020-12-31 | ₩59.37 Billion ≈ $40.23 Million |
₩1.90 Billion ≈ $1.29 Million |
0.032x | -54.41% |
| 2019-12-31 | ₩60.36 Billion ≈ $40.90 Million |
₩4.24 Billion ≈ $2.87 Million |
0.070x | -22.75% |
| 2018-12-31 | ₩59.11 Billion ≈ $40.06 Million |
₩5.38 Billion ≈ $3.64 Million |
0.091x | -0.57% |
| 2017-12-31 | ₩62.09 Billion ≈ $42.08 Million |
₩5.68 Billion ≈ $3.85 Million |
0.091x | -20.17% |
| 2016-12-31 | ₩61.66 Billion ≈ $41.79 Million |
₩7.07 Billion ≈ $4.79 Million |
0.115x | +16.09% |
| 2015-12-31 | ₩56.90 Billion ≈ $38.56 Million |
₩5.62 Billion ≈ $3.81 Million |
0.099x | +24.53% |
| 2014-12-31 | ₩51.53 Billion ≈ $34.92 Million |
₩4.09 Billion ≈ $2.77 Million |
0.079x | -- |
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more